Search Results
Showing Results for neurodegenerative diseases
As touchNEUROLOGY approaches 20 years of providing education for busy neurologists, we are looking to the future—and it certainly looks bright!
Dr Bedia Samanci is a 2025 touchNEUROLOGY Future Leader, and is already making a significant impact in the field of clinical neurology. In this Q&A we discuss advanced neuroimaging, biomarker discovery and the integration of machine learning into neurological diagnostics. Areas that promise to shape the future of patient care.
Prof. Michael Schöll joins us at EAN 2025, to discuss how plasma biomarkers are reshaping Alzheimer’s diagnostics, though not yet in routine clinical use. He explains the growing role of biomarkers like p-tau217 in MCI pathways, the challenges clinicians face without clear guidelines, and why blood-based and digital biomarkers, alongside new therapies, are the future of dementia care.
Prof. Joaquim Ferreira shares insights from EAN 2025 on the future of Parkinson’s disease care. He discusses realistic timelines for DMTs, the evolving role of gene therapy for genetic subgroups, and the potential of adaptive deep brain stimulation. Prof. Ferreira also highlights the growing importance of optimizing current treatments, interdisciplinary care, and addressing persistent challenges such as gait disturbance, dyskinesia, and cognitive decline.
At EAN 2025, Prof. K. Ray Chaudhuri shares insights into cutting-edge Parkinson's drug delivery methods, the future of biomarker-driven care, advances in managing sleep disturbances, and the vital role of lifestyle modifications in optimizing patient outcomes.
Prof. Bengt Winblad shares insights EAN 2025 on the evolving landscape of Alzheimer’s diagnosis and treatment. He discusses the growing role of biomarkers, the balance between early detection and clinical accuracy, and the challenges posed by the COVID-19 pandemic on dementia care. Prof. Winblad also explores emerging therapies, including monoclonal antibodies, and highlights the importance of combining biomarkers with cognitive testing to improve diagnostic precision and address the rise in undiagnosed cases post-pandemic.
Physician burnout is at a critical point. In this episode, Nicky speaks with Dr Alfred Atanda about why so many physicians are burning out and what can be done to change the trend. From personal experience to system-wide solutions, Dr Atanda shares valuable insights on improving physician well-being and building a more effective healthcare culture.
What if your medical degree could launch more than a clinical career? In this candid and compelling read, Dr Jon Edelson shares his lessons for early-career clinicians ready to think beyond the bedside and explore the business of medicine.
Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disorder of upper and lower motor neurons that results in progressive motor impairment. ALS is the most common disease of motor neurons with an annual incidence of approximately 1.7–2.5 per 100,000 people. It is a ...
The Lumipulse G pTau217/ß-Amyloid 1-42 Plasma Ratio test, the first diagnostic blood test designed to aid in the evaluation of Alzheimer’s disease (AD), has been cleared by the US Food and Drug Administration (FDA). The Lumipulse G pTau217/ß...
In this episode, we explore the future of continuing medical education (CME) with the team behind touchIME. Hannah Fisher and Matthew Goodwin share insights into global and US trends, the importance of patient inclusivity and how educational outcomes are evolving to better measure the direct impact of learning on clinical practice and patient care.
Amyotrophic lateral sclerosis (ALS) is characterized by the degeneration of both upper and lower motor neurons, which ultimately leads to muscle weakness, atrophy, spasticity and contractures.1 ALS typically manifests in the 50–60 years age range, although familial cases may present in ...
Brain Awareness Week, taking place from March 10-16, 2025, is a global campaign dedicated to fostering public enthusiasm and support for brain science, organised by the Dana Foundation. Each March, participants worldwide organize imaginative activities that highlight the wonders of the brain and the profound impact of neuroscience on our daily lives.
The first prenatal treatment for spinal muscular atrophy showed promise in a single case report.
As we move through 2025, touchNEUROLOGY remains committed to sharing the latest developments in Parkinson’s disease (PD). Our society partners at Parkinson’s Europe have outlined three key hopes for the year ahead—each representing a crucial step toward better support, understanding and treatment for the Parkinson’s community.
Log into your Touch Account
Earn and track your CME credits on the go, save articles for later, and follow the latest congress coverage.
Sign up with an Email
Or use a .
This Functionality is for
Members Only
Explore the latest in medical education and stay current in your field. Create a free account to track your learning.
